The tumor suppressor p53 protein is activated by genotoxic stress and regulates genes involved in senescence, apoptosis and cell-cycle arrest. Nine p53 isoforms have been described that may modulate suppressive functions of the canonical p53 protein. Among them, D133p53 lacks the 132 proximal residues and has been shown to modulate p53-induced apoptosis and cell-cycle arrest. D133p53 is expressed from a specific mRNA, p53I4, driven by an alternative promoter P2 located between intron 1 and exon 5 of TP53 gene. Here, we report that the P2 promoter is regulated in a p53-dependent manner. D133p53 expression is increased in response to DNA damage by doxorubicin in p53 wild-type cell lines, but not in p53-mutated cells. Chromatin immunoprecipitation and luciferase assays using P2 promoter deletion constructs indicate that p53 binds functional response elements located within the P2 promoter. We also show that D133p53 does not bind specifically to p53 consensus DNA sequence in vitro, but competes with wild-type p53 in specific DNA-binding assays. Finally, we report that D133p53 counteracts p53-dependent growth suppression in clonogenic assays. These observations indicate that D133p53 is a novel target of p53 that may participate in a negative feedback loop controlling p53 function.
Introduction
The tumor suppressor TP53 gene is one of the most frequently altered genes in human cancers (Petitjean et al., 2007) . The expression of its product, the p53 protein, is tightly controlled through protein interaction with the E3-ubiquitin ligase Hdm2 that induces p53 proteasome-dependent degradation (Haupt et al., 1997; Kubbutat et al., 1997) . Under stress, p53 is posttranslationally modified, escapes to Hdm2-mediated degradation, accumulates in the nucleus and regulates the transcription of several target genes involved in growth suppressive responses including cell-cycle arrest, senescence and apoptosis. Among cell-cycle arrest genes, p21
WAF1/CIP1 encodes a cyclin-dependent kinase inhibiting cyclin:CDK complexes at both G1/S and G2/M (el-Deiry et al., 1993; Waldman et al., 1995) . p53-dependent apoptosis is mediated through several distinct pathways involving genes, such as BAX or PUMA, that induce mitochondrial apoptosis through caspase activation (Miyashita and Reed, 1995; Villunger et al., 2003) . A complex and critical question is to understand the molecular mechanisms by which p53 induces different types of suppressive responses, depending on the nature and intensity of the stress as well as on the cell and tissue characteristics (Vousden, 2006) .
TP53 has been shown to produce nine isoforms (Bourdon et al., 2005) . These isoforms combine three different N-terminal transactivation domains (TADs) (the full-length N-terminus present in p53, D40 and D133) with three different C-terminal oligomerization domains (a, b and g, generated by alternative splicing) (Marcel and Hainaut, 2009 ). The D40p53 and D133p53 isoforms lack, respectively, 39 residues, which carry the main TAD, or 132 residues, corresponding to the TAD, the proline-rich region and the proximal part of the DNA-binding domain ( Figure 1a ) (Courtois et al., 2002; Bourdon et al., 2005) . D40p53 isoform binds p53 response elements (p53REs), but has no intrinsic transactivation capacity, resulting in the inhibition of p53 transcriptional and growth suppressive functions (Courtois et al., 2002; Ghosh et al., 2004) . Recent studies have shown that D133p53 can also inhibit both p53 transcriptional activity in reporter assays and p53-dependent apoptosis (Bourdon et al., 2005; MurrayZmijewski et al., 2006) . Thus, p53 isoforms may regulate some aspects of p53 functions. The expression of both p53 and D40p53 is controlled by the P1 promoter located upstream of exon 1 (Figure 1a ) (Tuck and Crawford, 1989; Ghosh et al., 2004) . A second promoter, P2, has been identified within TP53 gene, in a region that spans the distal part of intron 1 to the proximal part of exon 5, covering about 1.5 kb (Bourdon et al., 2005) . The resulting transcript, p53I4, carries the 3' end of intron 4 followed by all exons from 5 to 11 and supports D133p53 synthesis. However, the regulation of the P2 promoter is still unknown.
TP53 belongs to a family that contains two other members, TP63 and TP73, with strong functional and structural similarities (Kaghad et al., 1997; Yang et al., 1998) . These two genes contain an internal promoter, which regulates the production of N-truncated isoforms (Kaghad et al., 1997; Ishimoto et al., 2002) . The p53 protein has been shown to bind the internal promoter of TP63 and TP73 and to act either as a negative or positive transcription factor (Grob et al., 2001; Harmes et al., 2003) . These observations led us to investigate Figure 1 Correlation between p53 and D133p53 expression. (a) The TP53 gene contains two promoters. The proximal P1 promoter regulates the expression of the p53 protein, which contains a transactivation domain (TAD), a DNA-binding domain (DBD), an oligomerization domain (OD) and a basic domain (BD). Fragment from intron 1 to exon 5 (box) contains the alternative P2 promoter that regulates the expression of the truncated D133p53 isoform. (b) Increased amounts of pcDNA3-p53 vector, expressing p53 cDNA, were transfected in A549 cells. p53 protein was detected by western blot 48 h post-transfection using DO-7 antibody (black arrowhead) and D133p53 using DO-12 antibody in the same extracts (white arrowhead) (left panel). p53I4 mRNA levels were quantified by realtime PCR using a forward primer hybridizing within intron 4 (left panel). Increased expression of p53 was correlated with an increased expression of D133p53 at both protein and mRNA levels. Ku80: loading control; *Po0.05; **Po0.01. (c) siRNA-targeting p53I4 mRNA, which encodes D133p53 isoform, was introduced in A549 cells. The expression of p53I4 mRNA (left panel) and expression of p53 and D133p53 proteins (right panel) were analyzed, respectively, by real-time PCR or western blot. siRNA treatment reduces the expression levels of both p53I4 mRNA and D133p53 protein, whereas it not affects p53 expression levels. (d) In A549 cells, p53 expression was specifically knocked-down using a siRNA directed at exon 4 and D133p53 expression was analyzed at protein (left panel) and mRNA (right panel) levels. Decrease of p53 expression was correlated with a decreased expression of D133p53 at mRNA, but not at protein levels. Ku80: loading control. The DO-7 western blot was exposed for 1 min in (a) and for 10 min in (b). 
Results

D133p53 expression correlates with p53 protein levels
To determine the function of p53 in D133p53 expression, we first overexpressed p53 in p53-expressing A549 cell lines using pcDNA3-p53 vector that contains p53 cDNA ( Figure 1b ). The p53 protein levels were verified using DO-7 antibody, which recognizes an epitope (18-23) present in the N-terminal domain of p53, but absent in D133p53 (Figure 1b , left panel). To detect D133p53 protein, we used DO-12 antibody, which recognizes a part of the DNA-binding domain common to both proteins (260-264), but allows to distinguish them on the basis of their different electrophoretic motilities (Supplementary Figure 1a) . To verify that the 34 kDa band corresponds to D133p53, we used a siRNA that specifically targets p53I4 mRNA, encoding D133p53 protein. As shown in Figure 1c and in Supplementary  Figure 1b , this siRNA significantly reduced both p53I4 mRNA levels and the intensity of the 34 kDa band, while not affecting the levels of the canonical p53 protein. After p53 overexpression, an increase in D133p53 protein was observed that correlated with increased amounts of transfected pcDNA3-p53 vector and of expressed p53 protein (Figure1b; Supplementary  Figure 1a) . A similar increase in p53I4 mRNA was also detected in these conditions with a significant twofold increase in the presence of 1.5 mg/ml of pcDNA3-p53-transfected vector (Figure 1b , right panel). Comparable effects were observed in another cell line expressing detectable basal levels of wild-type p53, MN1 (data not shown). These observations show that overexpression of p53 induces an increase in D133p53 isoform at both mRNA and protein levels. To further show that p53 regulates p53I4 mRNA levels, we silenced p53 expression in A549 cells. A siRNA-targeting exon 4 of TP53 gene was used to selectively eliminate full-length, but not p53I4 transcript. At protein level, p53 silencing did not result in a detectable variation of D133p53 despite reducing p53 protein levels by >70% (Figure 1c, left panel) . In contrast, at mRNA level, a significant decrease of 40% in p53I4 was observed (Figure 1c, right panel) . These data show that removal of p53 in A459 cells decreases basal levels of p53I4 mRNA, but not of D133p53 protein. This suggests that p53 silencing affects D133p53 transcription, but that within the time course of this experiment, the effect of this decrease is not detectable at the protein level, maybe because of its relatively long half-life.
D133p53 expression is modulated in a p53-dependent manner in response to stress To investigate the possible regulation of D133p53 by p53 in response to stress, we assessed p53I4 mRNA expression in response to DNA damage induced by doxorubicin in A459 cells (Figure 2a) . Protein accumulation of p53 and Hdm2, a p53-target gene, was verified by western blot in response to two different doses of doxorubicin at 8 h of treatment. We observed a dosedependent increase in D133p53 protein expression correlated with a concordant increase in p53I4 mRNA, reaching a significant threefold increase at the highest dose. However, this dose-dependent increase of D133p53 is limited in cells transfected with a siRNA-targeting p53I4 mRNA (Supplementary Figure 1c) . These observations indicate that D133p53 is induced by p53 in response to DNA damage.
To assess the impact of p53 on D133p53 expression at basal levels, we next used the MN1 breast cancer cell line grown in estrogen-free conditions ( Figure 2b ). This condition has been shown to reduce basal levels of p53 in estrogen-dependent breast cancer cell lines (Hurd et al., 1997) . At protein level, estrogen deprivation resulted in a marked decrease in p53 and Hdm2 expression after long deprivation times. These variations were paralleled with matched variations in D133p53 expression, at both protein and mRNA levels. Using real-time PCR, the decrease after 12 days of deprivation (20% decrease) was statistically significant. Together, these observations indicate that treatments regulating basal levels of p53 protein, either positively or negatively, exert matched effects on D133p53 mRNA and protein levels.
D133p53 isoform interferes with p53 DNA-binding and growth suppression It has been shown that D133p53 isoform can form hetero-oligomers with p53 protein and can inhibit p53-dependent transcription in luciferase assays (MurrayZmijewski et al., 2006; Chen et al., 2009) . To investigate whether D133p53 isoform may modulate p53 DNAbinding activity, we performed electro-mobility-shift assays (EMSA) using a 32 P-labeled p53RE consensus oligonucleotide ( Figure 3a ). Western blot confirmed the presence of the two proteins at expected levels (Supplementary Figure 2a ). In the presence of p53 alone, a shift was observed, which was both super-shifted and stabilized by the addition of the monoclonal PAb421 antibody, as described earlier (Figure 3a ) . In the presence of D133p53, no shift was observed, whereas in the presence of the two proteins, D133p53 seems to significantly decrease the super-shift generated by the formation of DNA:p53:PAb421 complex ( Figure 3a ; Supplementary Figure 2b ). These observations indicate that D133p53 does not bind p53RE DNA on its own, which is consistent with the p53 regulates D133p53 expression V Marcel et al notion that it lacks L1 loop of the DBD (residues 117-142) (Bourdon et al., 2005) . Furthermore, it reduces p53 DNA-binding activity, maybe by forming hetero-oligomers unable to bind p53RE DNA. To verify this hypothesis, EMSA were conducted using DO-7 antibody in addition to PAb421 (Supplementary Figure 2b) . Indeed, hetero-oligomers containing D133p53, which lacks DO-7 epitope, would undergo an incomplete shift in the presence of DO-7 antibody. No such shift was detected, suggesting that p53:D133p53 complexes are unable to bind specifically to p53RE DNA. The above results suggest that D133p53 isoform may inhibit p53 transcriptional capacity by inhibiting its DNA-binding activity.
To determine whether such an effect may inhibit p53 suppressive function, a colony formation assay was performed using p53-null H1299 cells transfected with vectors expressing p53, D133p53 or both (Figure 3b ). After 14 days of selection, cells transfected with empty vector were spread over the surface of the well. Conversely, expression of p53 drastically reduced colony formation, in agreement with its growth suppressive activity. When compared with empty vector, cells transfected with D133p53 tended to form less colonies; however, D133p53 did not exert a suppressive effect similar to the one of p53. When co-transfected at equal amounts, D133p53 at least partially prevented the suppressive effect of p53. These observations suggested that D133p53 may counteract p53 suppressive function.
p53 transactivates the internal P2 promoter of TP53 gene D133p53 expression at mRNA levels was correlated with the expression levels of p53 protein, suggesting that p53 transactivates the internal P2 promoter. To test this hypothesis, we generated a luciferase reporter driven by the P2 promoter sequence identified by Bourdon et al. (2005) , consisting in a 1.5 kb fragment from intron 1 to exon 5 of TP53 gene. This luciferase reporter was cotransfected in p53-null H1299 cells with various amounts of pcDNA3-p53 expression vector (Figure 4a , right panel). The expression of exogenous p53 protein and of its target gene Hdm2 was verified by western blot (Figure 4a, left panel) . The basal transcriptional activity of the P2 promoter in the absence of p53 was fivefold higher than the one of the Basic promoterless luciferase vector. In the presence of pcDNA3-p53 vector at concentrations above 0.25 mg/ml, luciferase activity was significantly increased by about sixfold over the basal transcriptional activity of the P2 promoter. The luciferase activity was concordant with p53 expression levels ( Figure 4a , left panel) and showed a dosedependent increase with amounts of transfected pcDNA3-p53 vectors between 25 and 500 ng/ml (Supplementary Figure 3a) . These results indicate that the P2 promoter activity is regulated by p53.
It has been reported that D40p53 isoform lacks part of the TAD and has no transcriptional activity toward reporter system carrying p53REs (Courtois et al., 2002; Ghosh et al., 2004) . Different amounts of D40p53 were transfected in the presence of the luciferase Figure 3b) . Compared with the significant increase in luciferase activity with pcDNA3-p53 vector, D40p53 alone has only minimal, non-significant effects on luciferase activity. These data suggest that p53 transcriptional activity is required to transactivate the P2 promoter.
p53REs are located within the P2 promoter The p53 protein binds to response elements defined as repeats of a palindromic consensus sequence (5 0 -RRRCWWGYYY-3 0 ) (el-Deiry et al., 1992). We used MatInspector software to identify putative p53RE by analyzing the fragment from intron 1 to exon 5 of TP53 that corresponds to the P2 promoter (Cartharius et al., 2005) . This DNA fragment contains four putative p53REs (Figure 4b; Supplementary Figure 4a) . The first p53RE, termed as RE-1, is located in the 5 0 end of intron 3. RE-2 is contained within exon 4, whereas the RE-3 and -4 are located 9 bp apart in intron 4 just upstream of the initiation start site of transcription. None of these REs shows a perfect match with the p53 consensus, the degree of matching varying from 60% (RE-3) to 85% (RE-2) (Supplementary Figure 4b) .
To evaluate the contribution of these p53REs, we generated four deletion mutants of the promoter into the luciferase reporter (Figure 4b ). In the absence of p53, these reporters showed differences in their basal transcriptional activity, suggesting that they may contain different regulatory elements in addition to p53 (Supplementary Figure 5a) . These differences in basal activities have been normalized to evaluate the activation induced by p53. As shown in Figure 4b , p53 clearly stimulated the activity of the three P2 luciferase constructs (9-10-fold over Basic): P2 (containing RE-1 to RE-4); P2D1 (RE-1 to RE-4) and P2D2 (RE-2 to RE-4). However, it had only minor effects on P2D3 (RE-3/4) and P2D4 (no RE) (less than twofold over Basic). These results suggest that, among the four putative REs, RE-2 may have the major effect.
To investigate the function of RE-2 in greater details, we introduced mutations at critical bases of RE-2 by successive rounds of site-directed mutagenesis (Figure 4c ). The resulting reporter constructs, termed as P2 Mut1 and Mut2, carry, respectively, 2 or 4 introduced mismatches with the consensus sequences. In the presence of the Figure 3 Effects of D133p53 on p53 biochemical and biological properties. (a) Electro-mobility-shift assays (EMSA) measuring DNA-binding activity. p53-null H1299 cells were co-transfected with a constant amount of pcDNA3-p53 vector (0.5 mg/ml) in the presence of increasing amounts of pcDNA3-D133p53 vector (0.25-1 mg/ml). Nuclear extracts were incubated with a 32 P-labeled p53RE oligonucleotide, with or without PAb421, which stabilizes and super-shifts p53:DNA complexes. DNA:p53 shifts and DNA:p53:PAb421 super-shift are indicated by arrowheads. *: non-specific band. (b) Colony formation assays were performed using p53-null H1299 cells transfected with 0.5 mg/ml of wild-type pcDNA3-p53 vector and/or ÀD133p53 vector during 14 days under 0.5 mg/ml of neomycin selection. As compared with wild-type p53, D133p53 did not suppress cell growth (60% of colonies compared with empty conditions) and partially reverted the suppression induced by wild-type p53 (10% in presence of p53 compared with 40% in presence of both p53 and D133p53).
p53 regulates D133p53 expression V Marcel et al pcDNA3-empty vector, the three P2 plasmids exhibited the same luciferase activity, indicating no abolition of their basal transcriptional activities (Supplementary Figure 5b) . In the presence of pcDNA3-p53 vector, the promoter activities of P2 Mut1 and Mut2 were reduced by about 40% as compared with wild-type P2 (Figure 4c ). These observations suggest that RE-2 located in exon 4 participate in the p53-dependent regulation of P2 promoter, but does not account on its own for the full activation of P2 by p53. p53 binds the internal promoter P2 of TP53 gene We used chromatin immunoprecipitation (ChIP) to analyze the binding of p53 on different segments of the P2 promoter in A549 cells in basal conditions. The DO-7 antibody was used to immunoprecipitate p53 and non-immunized IgG were used as negative control ( Figure 5 ). After ChIP, five PCR products were analyzed ( Figure 5a ). As controls, we used primers designed to amplify the p21 WAF1/CIP1 promoter (positive Figure 4 P2 promoter activity is regulated by p53. (a) In p53-null H1299 cells, luciferase assays (right panel) were performed using a luciferase reporter under the control of the 1.5 kb segment of TP53 from intron 1 to exon 5, in the presence of increasing amounts of pcDNA3-p53, the expression of which was verified by western blot (left panel). Increase in luciferase activity was concordant with p53 protein levels. Basic: promoterless luciferase reporter; P2: luciferase reporter driven by TP53 segment; Ku80: loading control; *Po0.05; **Po0.01. (b) MatInspector software (Cartharius et al., 2005) was used to predict four putative p53-binding sites (RE-1 to -4) in the promoter P2. Luciferase reporter deletion constructs were engineered as pictured and tested in the presence of p53. Mean fold induction was calculated as the ratio between luciferase activity of each construct in the presence of pcDNA3-empty or -p53 vector. p53 induced at least a fivefold increase of luciferase activity using P2, D1 or D2. In contrast, no induction was observed using D3 and D4. (c) Luciferase assays (right panel) were performed in cells co-transfected with pcDNA3-p53 vector and with either one of two plasmids carrying mutations in RE-2 (P2 Mut1 and P2 Mut2; left panel). Mutations in p53RE induced a 40% decrease of luciferase activity. p53RE: consensus sequence of p53RE; star: mismatch between p53RE and RE-2 in the promoter P2.
p53 regulates D133p53 expression V Marcel et al control) and exon 8 of TP53 gene (negative control). ChIP with IgG did not generate any amplification. In contrast, ChIP with DO-7 antibody generated an amplification signal for p21 WAF1/CIP1 promoter, but not for TP53 exon 8. With P2 promoter fragments, no amplification was observed with primers targeting a DNA fragment containing RE-1 (Figure 5a ). In contrast, amplifications were observed for fragments encompassing RE-2 and RE-3/4. These observations suggest that p53 physically binds several p53REs located between exon 4 and intron 4, but not in intron 3.
Mutant p53 does not induce D133p53 expression
To further assess the specificity of the wild-type p53 effect on the P2 promoter, we analyzed its regulation in response to DNA damage by doxorubicin in several cell lines expressing p53 with different functional status (Figure 6a ). In wild-type p53 cells, doxorubicin treatment induced both p53 and D133p53 expression as expected. In contrast, in three cell lines expressing a nonfunctional p53 protein, treatment with doxorubicin had either no or only minimal effects on the expression of p53 and D133p53.
These observations were extended by analyzing the effects of several common 'hotspot' TP53 mutants on the expression of the P2 luciferase reporter (Figure 6b) . In contrast to wild-type p53, none of these mutants succeeded in activating the reporter. These observations support the notion that only wild-type p53 with functional capacities transactivates the P2 promoter leading to D133p53 expression.
Discussion
Recently, it has been shown that TP53 gene is expressed as several isoforms (Bourdon et al., 2005) . Among them, only D133p53 is regulated by an alternative promoter, P2, located within TP53 (Bourdon et al., 2005) . Its overexpression has been observed in squamous cell carcinoma of the head and neck as well as in breast cancers, suggesting a function of D133p53 in tumorigenesis (Bourdon et al., 2005; Boldrup et al., 2007) . However, the biological regulation and function of D133p53 are still unknown. Here, we have analyzed the P2 promoter and we show that its activity is regulated by p53. First, modulation of wild-type p53 expression induces D133p53 expression at both mRNA and protein levels. Second, the P2 promoter contains p53REs, which are involved in p53 responsiveness. Third, D133p53 prevents the binding of wild-type p53 to DNA segment containing its consensus sequence and inhibits p53 suppressive activity in a clonogenic assay. These data suggest that D133p53 may contribute to an auto-regulatory process by which p53 controls its own suppressor function.
At the time of D133p53 identification, several evidences supported the presence of an internal promoter involved in the production of D133p53 (Bourdon et al., 2005) . A transcript, p53I4, initiated within intron 4, but exhibiting the same splicing pattern as full-length p53 mRNA downstream of exon 5, was observed in several human cell lines, in Drosophilia and Zebrafish (Bourdon et al., 2005; Chen et al., 2005) . In addition, a 1.5 kb segment of TP53 spanning from intron 1 ( þ 10810) to exon 5 ( þ 12396) conferred a sixfold induction to a luciferase reporter (Bourdon et al., 2005) . In this study, we confirm that the same TP53 sequence possesses a promoter activity (fivefold induction of reporter) and we show that this segment confers responsiveness toward wild-type, but not mutant p53. Furthermore, using MatInspector software, we identified four putative p53REs upstream of the transcription initiation site. These p53RE have a degree of degeneration, which is in the same range as p53REs of many common p53-target genes (Menendez et al., 2007) . Using luciferase and ChIP experiments, we show that transcriptional activation by p53 is dependent on two contiguous regions containing p53REs: one in the 3'-end of exon 4 that correlates with the main p53 responsiveness and one in intron 4. These observations correlate with the one of Chen et al. (2009) , who recently reported that the internal P2 promoter of TP53 Zebrafish was induced by p53 through two close p53REs located in intron 4, just upstream the initiation site of transcription. These authors suggest that the two response elements operate in a cooperative manner. These data suggest that human D133p53 isoform and its zebrafish Figure 5 Binding of p53 on P2 promoter. (a) Chromatin immunoprecipitation assay (ChIP) for p53 protein onto P2 promoter in wild-type p53-expressing A549 cells in basal conditions. Purified DNA immunoprecipitated by p53 was analyzed by PCR using specific primers to amplify regions located in p21 WAF1/ CIP1 promoter (positive control), in exon 8 of TP53 gene (negative control) and in three parts of promoter P2 containing the putative p53REs RE-1, RE-2 and RE-3/4). Input: ChIP positive control; IgG: ChIP negative control; DO-7: immunoprecipitation using DO-7 antibody. (b) In A549 cells, p53 was immunoprecipitated using DO-7 antibody and immunodetected using CM1. A band of low intensity was detected in DO-7 immunoprecipitated sample. p53 regulates D133p53 expression V Marcel et al homolog are regulated by a conserved mechanism involving p53 protein.
In addition to in vitro data, we reported p53-dependent regulation of D133p53 isoform in cancer cell lines expressing wild-type, but not mutant p53. To detect D133p53, we have used the monoclonal antibody DO-12 that recognize a p53 epitope (260) (261) (262) (263) (264) . This antibody has been described as the most appropriate to detect D133p53 among a panel of seven common p53 antibodies. Using siRNA-targeting p53I4 mRNA to specifically knock-down D133p53, we verified that the 34 kDa band indeed corresponds to D133p53 protein (Supplementary Figure 1b) (Bourdon, 2007) . In response to DNA damage induced by doxorubicin, an increase in D133p53 expression followed the accumulation of p53 by about 8 h, a time-course compatible with that of products of other p53-regulated genes such as Hdm2, BAX or p21 WAF1/CIP1 (Figure 2a and data not shown). In Zebrafish, a similar lag of 6 h has been observed between induction of p53 and D113p53 on ribosomal stress (Danilova et al., 2008) . The p53-dependent regulation of D133p53 expression in response to stress was also reported in response to g-rays exposure (Chen et al., 2009) . Although several reports have described induction of D133p53 expression in response to stress, no data on basal activity of P2 promoter have been reported. Here, using siRNA and estrogen deprivation that both results in a reduction of basal p53 expression, we observed a decrease in D133p53 expression at mRNA levels. These observations suggest that p53 has an important function in the maintenance of D133p53 expression at basal levels. Although p53 siRNA did not have a detectable effect on D133p53 protein expression after 48 h, this may be explained by the fact that D133p53 lacking the Hdm2-binding domain may escape Hdm2-mediated degradation, being thus more stable than p53 (Haupt et al., 1997; Kubbutat et al., 1997) .
In contrast to p53, D133p53 lacks the first 30 residues of the DNA-binding domain encoding the L1 loop and part of the loop-sheet-helix motif that form the structure binding to the major groove of DNA in p53RE (Cho et al., 1994) . As expected, we observed that this protein is unable to bind DNA containing the p53 consensus sequence using the same in vitro conditions than for p53. However, D133p53 could decrease the binding capacity of p53 on p53RE. As it has been described that p53 and D133p53 can form hetero-tetramers (Chen et al., 2009) , our data suggest that D133p53 tetramers lack sequencespecific DNA-binding capacity. The inhibition of p53-binding capacities by D133p53 is in agreement with the inhibitory effect of D133p53 on both p53 transcriptional activity and p53-dependent apoptosis (Bourdon et al., 2005; Murray-Zmijewski et al., 2006) . Here, we provide support for long-term anti-suppressive effects of D133p53 by showing that co-expression of D133p53 Luciferase assays were performed in the presence of different mutant p53 as indicated. As compared with wild-type p53, mutant p53 had no effect on P2 promoter activity. Wt: wild-type p53; *Po0.05. and p53 could partially restore the proliferation capacity of H1299 cells in a clonogenic assay. However, despite the accumulation of evidences suggesting that D133p53 may counteract p53 suppressive function, there is still limited information available on the physiological function of D133p53. One of the problems is that D133p53 seems to be expressed at low levels as compared with p53, in particular after DNA damage. Recent results in Zebrafish shed a light on a possible mechanism of action (Chen et al., 2009) . They observed that the Zebrafish homologous of D133p53 could antagonize p53-induced apoptosis through activating Bcl-2L (homologous of the human Bcl-xL), and that knockdown of D113p53 enhanced p53-mediated apoptosis under stress conditions. These results are consistent with the ones reported here and indicate that small changes of D133p53 may contribute to a novel feedback pathway that modulates the p53 response.
In this study, we observed that the internal P2 promoter involved in D133p53 expression is regulated by p53. This feature is a familial trait also observed in the other TP53 gene family members, TP63 and TP73, which express N-truncated proteins that are regulated by internal promoters responsive to wild-type p53 (Grob et al., 2001; Harmes et al., 2003) . These N-truncated proteins participate in auto-regulatory feedback loops that regulate p53 suppressive functions. This model seems to be relevant for D133p53 isoform as well. Thus, D133p53 is another player involved in these autoregulatory feedback loops, which may selectively interfere with p53 capacity to transactivate target genes. It remains to be determined in which cell type and stress type context this regulation may have a major function.
Materials and methods
Cell culture
Two human cell lines expressing wild-type TP53 were employed: lung A459 and breast ZR75.1 cells. Human p53-null H1299 cells were used for luciferase assays and EMSA. Two human breast cell lines expressing mutant TP53, BT474 (E285K) and T47D (L194F) were used. Two isogenic breast cell lines derived from MCF-7 were employed, MN1 (stably transfected with an empty vector) and MDD2 (expressing a mini-peptide exerting negative effect on the endogenous wildtype p53) (Bacus et al., 1996) . Cells were treated for 8 h with doxorubicin (0.2 or 0.4 mM). Breast MN1 cells were treated with medium deprived of both Red phenol and estradiol.
Vectors
Exogenous p53 isoforms (p53, D40p53 and D133p53) were produced using pcDNA3 vectors containing human cDNA of each isoforms (Courtois et al., 2002) . Five mutant pcDNA3-p53 were used (R175H, Y220C, G245S, R248W and R273H). The pcDNA3-empty vector was used as a negative control. Several luciferase reporter vectors were developed using pGL3-Basic, a promoterless luciferase plasmid (Promega, Fitchburg, WI, USA). The pGL3-P2 (or P2) vector contains the human P2 promoter (from intron 1 to exon 5) upstream of Luciferase gene. Four deleted and two mutant vectors were constructed using P2 vector (Supplementary Table 1 ). The pGL3-Basic was used as negative control to standardize experiments and phRL-null plasmid as control of transfection efficiency to normalized experiments.
Transfection
The pcDNA3 expression vectors (1.5 mg/ml completed with pcDNA3 empty) were transfected using 9 ml of Fugene (Roche, Indianapolis, IN, USA) in A549 and H1299, harvested 48 h latter for overexpression and 24 h latter for EMSA assays. Silencing of p53 mRNA was performed in A549 cells seeded in antibiotic-free medium and directly transfected with 20 nM of either scramble or p53-targeted siRNAs (Eurogentec, Liege, Belgium) (Supplementary Table 1 ) using 12 ml of Hyperfect (Qiagen, Huntsville, AL, USA). Cells were transfected twice at 24 h interval and harvested after 48 h of treatment. For luciferase assays using Fugene (Roche), 500 ng/ml of pGL3 plasmids were transfected with 10 ng/ml of phRL-null and with 1 mg/ml of pcDNA3 expression vectors. Cells were harvested 48 h post-transfection and luciferase activity was analyzed using Dual Luciferase Reporter Assay System (Promega).
Real-time quantitative RT-PCR Total RNA was extracted using Nucleospin RNA II kit (Machery-Nalgene, Duren, Germany) and reverse transcription was performed using random primers (Promega) and SuperScript II (Invitrogen, Carlsbad, CA, USA). RNA expression was analyzed by real-time quantitative RT-PCR using Brilliant SYBR Green Master Mix (Qiagen) and 0.4 mM of primers (Supplementary Table 1 ). The p53I4 mRNA expression level is normalized to that of Gapdh (lung cells) or of 28S (breast cells). The control of the experiment is used as the reference. All samples were analyzed in triplicates and two Q-PCRs were performed for each experiment.
Western blot
Proteins were extracted using RIPA-like buffer (50 mM Tris-HCl pH7.4, 250 mM NaCl, 0.1% SDS, 0.5% NP-40, 2 mM DTT, 1 mg/ml protease inhibitors) and were analyzed on a 10% SDS-polyacrylamide gel using several antibodies: DO-7 (monoclonal anti-p53 antibody specific of TAD; Dako, Cambridgeshire, UK); DO-12 (monoclonal anti-p53 antibody specific of DBD), which has been described as the most appropriate to detect D133p53 among a panel of seven common p53 antibodies (Bourdon, 2007) ; CM1 (polyclonal anti-p53 antibody; Novocastra, Newcastle, UK); Hdm2 (Abcam) and Ku80 (used as a loading control; Abcam). Detection was performed with the ECL kit (Amersham, Cambridge, MA, USA) by autoradiography.
Chromatin immunoprecipitation assay
In 100 mm plates, 3 Â 10 6 A549 cells were seeded. The following day, 1% formaldhehyde was added onto cells for 10 min at room temperature to cross-link proteins to DNA. Sonication was performed (twice: 10 Â (5 s on: 5 s off) at 21% amplitude) (Vibra cell 75041) and immunoprecipitation was carried out using 4 mg of DO-7 antibody (anti-p53) and protein G-agarose beads (Invitrogen). DNA:p53 complexes were dissociated by reverse cross-linking using NaCl 200 mM and DNA was extracted by phenol/chloroform. Immunoprecipitated DNA was amplified by PCR (Supplementary Table 1 ).
Electro-mobility-shift assay Nuclear cellular proteins of H1299-transfected cells were extracted and incubated with mixture containing 32 P-radiop53 regulates D133p53 expression V Marcel et al
